Manager TitleAgeSince
President - 30/07/2025
Compliance Officer - -
Chief Tech/Sci/R&D Officer - -
Change 5-day change 1-year change 3-year change Capi.($)
+2.12%+2.57% - - 180.02Cr
-0.62%-0.10%+50.70%+114.07% 1,03100Cr
-2.30%-3.90%+39.50%+66.07% 64TCr
-0.63%-1.94%+12.26%+74.38% 46TCr
-1.03%-2.88%+71.35%+39.69% 36TCr
-0.03%-3.91%+34.28%+39.35% 33TCr
-1.58%+0.39%+17.92%+25.77% 27TCr
-2.02%-3.20%+7.60%+8.38% 25TCr
-3.38%+0.29%+44.32%+51.54% 23TCr
-1.04%-2.56%+32.88%+96.82% 18TCr
Average -0.98%-0.36%+34.53%+57.34% 41.82TCr
Weighted average by Cap. -1.12%-0.35%+38.05%+69.18%
Logo Endo, Inc.
Endo, Inc. is a diversified specialty pharmaceutical company, which is engaged in transforming insights into life-enhancing therapies. The Company’s segments include Branded Pharmaceuticals, Sterile Injectables, Generic Pharmaceuticals, and International Pharmaceuticals. Its Branded Pharmaceuticals segment focuses on products that have inherent scientific, regulatory, legal and/or technical complexities and are marketed under recognizable brand names that are trademarked. Its Sterile Injectables segment includes a broad portfolio of approximately 40 critical care, maternal health, anesthesia and other products. Its Generic Pharmaceuticals segment includes a portfolio of approximately 85 generic product families, including solid oral extended-release products, solid oral immediate release products, liquids, semi-solids, and others. Its International Pharmaceuticals segment sells a variety of specialty pharmaceutical products outside the United States, primarily to customers in Canada.
Employees
3,116
  1. Stock Market
  2. Stocks
  3. NDOI Stock